argenx SE American Depositary Shares

About argenx SE American Depositary Shares

Argenx SE (ARGX) is a Dutch biopharmaceutical company specializing in innovative antibody-based therapies for rare autoimmune diseases. The company's flagship product, Vyvgart (efgartigimod), received FDA approval in December 2021 for generalized myasthenia gravis (gMG) treatment. Argenx expanded its portfolio with Vyvgart Hytrulo, a convenient subcutaneous formulation approved in 2022 for gMG and in 2024 for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). With a robust pipeline targeting primary immune thrombocytopenia, thyroid eye disease, and Sjogren's disease, Argenx demonstrates strong commitment to advancing rare disease treatments. Trading on NASDAQ under ticker ARGX, the company continues to establish itself as a leader in niche immunology therapeutics, offering investors exposure to high-growth biopharmaceutical opportunities.